Global Blood Therapeutics, Inc. (GBT)
(Delayed Data from NSDQ)
$55.18 USD
+1.34 (2.49%)
Updated May 3, 2019 04:00 PM ET
After-Market: $55.12 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
[GBT]
Reports for Purchase
Showing records 81 - 100 ( 340 total )
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Improving Pandemic Conditions are Expected to Foster Growth for Oxbryta Sales; Reit Buy and $75 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Q1: Oxbryta Building a Base; Pipeline Coming into Focus
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Long-Term Follow-up Data from Oxbryta?/SCD Ph3 Trial Published in The Lancet
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Revising 1Q21 Oxbryta Sales Estimates; Reit Buy and $75 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Industry: Medical - Biomedical and Genetics
Key Takeaways from Virtual NDR on April 1, 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Industry: Medical - Biomedical and Genetics
Implementing In-Licensing Strategy To Build Out Pipeline
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Industry: Medical - Biomedical and Genetics
Sanofi Exclusive In-License Deal Expands SCD Pipeline
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department